The Sequoia Project announced Wednesday that it’s forming a new Data Usability Workgroup to continue removing barriers to interoperability, and is calling for participants in advance of its first meeting later this month. WHY IT MATTERS The workgroup, part of the Sequoia Project’s Interoperability Matters cooperative, is focused first on…
INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800
PLYMOUTH MEETING, Pa., Sept. 28, 2020 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about…
Telehealth after dark: health systems can relieve clinician workload through nighttime virtual care
Smaller critical care hospitals may not have the patient volume to justify having a full-time physician for the night hours. This, said panelists during a recent HIMSS20 Digital presentation, can mean facilities leverage their daytime doctors for the job – leading, in turn, to burnout and decreased quality of care….
Pregnant and lactating women with COVID-19: Scant clinical research
Pregnant and breastfeeding women have been excluded from clinical trials of drugs to treat COVID-19, and as result, there is no safety data to inform clinical decisions. Such drugs include remdesivir according to a new article in the peer-reviewed journal Breastfeeding Medicine. Click here to read the article. Since pregnant…
Low enrollment stymies completion of rare disease clinical trials
Rare diseases are anything but rare when taken together. In the United States alone, they affect nearly 30 million people. Yet clinical trials for rare diseases are frequently incomplete or go unpublished in the medical literature, finds a study published today in the journal PLOS Medicine. Analyzing 659 trials, researchers…
GE Healthcare introduces Edison Developer Program to spur AI advancements
With its new Edison Developer Program, GE Healthcare hopes to speed the adoption and utility of artificial and machine learning applications and developer services for health systems, the company announced this week. WHY IT MATTERS GE’s Edison platform (named for the company’s founder) is designed to help providers gain easier…
Blood test could detect breast cancer five years before clinical signs
Blood test could detect start of breast cancer five YEARS before any clinical signs emerge, researchers claim Researchers at University of Nottingham say new blood test can detect cancer Test checks response of body’s immune system to antigens made by tumours If proved reliable could detect breast cancer up to five years before…
Clinical trial identifies new breast cancer drug as a potential therapy for glioblastoma
The Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali) for the treatment of recurrent glioblastoma. The agent, recently approved by the FDA for advanced breast cancer, is part of a newly-discovered…
First clinical guidance on anal sex after prostate cancer
UK doctors and surgeons have formulated what is probably the world’s first clinical guidance on anal sex before, during, and after diagnosis and treatment for prostate cancer. This consensus guideline, which is aimed at clinicians as well as gay and bisexual men with prostate cancer, recommends that men should abstain…
At Mount Sinai, telehealth reduces ER visits and hospitalizations
The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai Hospital had been relying on traditional office visits to connect with patients. THE PROBLEM These visits present patients with several barriers to care, however, including the inconvenience of travel and time off from work or school to…
How to gauge the value of precision medicine programs
Every health system understands the potential of precision medicine, but not all of them are quite ready to take the plunge into the complex and expensive project of actually starting a precision medicine initiative. At HIMSS19 on Monday, Dr. James Weese, vice president of Aurora Cancer Care at Milwaukee-based Advocate…